

Short Name	Full Title + Study Description	Type	Investigator	Contact
EMBARK HFpEF	An Exploratory, Open-Label, Proof-of-Concept, Phase 2a Study of Mavacamten (MYK 461) in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Troponin I and/or NT-proBNP	Drug	Dr. David Fermin	Katy Wachter Katy.Wachter@spectrumhealth.org 616.486.7481

This study is for patients who have been diagnosed with heart failure with preserved ejection fraction. This study will test whether the investigational drug, Mavacamten, can lower specific "biomarkers" in patients' blood levels that are signs of heart muscle injury and/or heart wall stress.